vericiguat + isosorbide mononitrate

**vericiguat + isosorbide mononitrate** is a combination of two small molecule vasodilators that act additively on the NO–sGC–cGMP pathway to produce vascular relaxation and reduce cardiac workload. **Vericiguat** is a direct stimulator of **soluble guanylate cyclase (sGC)**, increasing intracellular cyclic guanosine monophosphate (cGMP) levels independently of and synergistically with nitric oxide (NO), ultimately leading to vasodilation and improved myocardial and vascular function. It is primarily developed for **chronic heart failure** with reduced ejection fraction to reduce cardiovascular death and hospitalizations[1][3][4][5][6][8][9]. **Isosorbide mononitrate** is a nitrate that acts as a prodrug for NO, which activates sGC to increase intracellular cGMP and cause smooth muscle relaxation, notably in veins, reducing cardiac preload, used primarily as an anti-anginal agent[2][8]. The combination targets a central pathway in vascular regulation, but both lower blood pressure and may have additive pharmacodynamic effects, producing significant vasodilation and potential hypotension. Concomitant administration has been studied for hemodynamic safety, with Phase Ib data indicating no clinically significant additional adverse effects versus isosorbide mononitrate alone in stable coronary disease[8]. - Mechanism for vericiguat: direct allosteric stimulation of sGC and sensitization of sGC to endogenous NO - Mechanism for isosorbide mononitrate: NO donor, indirectly activating sGC via nitric oxide release - Primary indications: heart failure (vericiguat), angina/chronic coronary syndrome (isosorbide mononitrate) - Developers: Merck/Bayer (vericiguat)[1][3][6][7] - The combination is not an approved branded product but is a studied drug-drug co-administration.